Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V. Sputnik Light demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered.
The data was obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020 and April 15, 2021. An efficacy level of near 80% is higher than that of many two-dose vaccines.
In January 2021, the two-dose Sputnik V vaccine was also approved for use in Palestine under the emergency use authorization procedure.
To date Sputnik V has been authorized in 66 countries with total population of over 3.2 billion people.